Clinical Liver Disease

View Top 200 Chart

Back to Rankings Page

Natural Sciences
**Clinical Liver Disease**

Clinical Liver Disease (CLD), an official digital learning resource of The American Association for the Study of Liver Diseases is an interactive, up-to-date source of education, designed for physicians and healthcare providers caring for the patient with liver disease. CLD provides current and clinically relevant information through educational interventions every two months.

Latest Episodes:

The new standard of HCV therapy: Retreatment in experienced patients - Interview with Marc Ghany Aug 21, 2012

Show notes

Interview with Marc Ghany.

The new standard of HCV therapy: Treatment in therapy-naive patients - Interview with Paul Kwo Aug 21, 2012

Show notes

The paradigm for hepatitis C virus (HCV) treatment relies on pegylated interferon and ribavirin (PR) as agents that enhance endogenous mechanisms for viral clearance and are dependent on host factors.

A brief history of the treatment of viral hepatitis C, Leonard Seef and Doris Strader - Article Reading Aug 21, 2012

Show notes

In the early 1960s, when only hepatitis types A and B were recognized, treatment was focused on the acute illness and consisted of strict bed rest, a nutritious diet, and the judicious use of medications.

A brief history of the treatment of viral hepatitis C - Interview with Leonard Seef and Doris Strader Aug 21, 2012

Show notes

Interview with Leonard Seef and Doris Strader

Demographics of hepatitis C virus today, Gary L Davis - Article Reading Aug 21, 2012

Show notes

It is currently estimated that 3 to 4 million individuals in the United States and up to 170 million individuals worldwide are chronically infected with hepatitis C virus (HCV).

Demographics of hepatitis C virus today - Interview with Gary L Davis Aug 21, 2012

Show notes

Interview with Gary L Davis.

Issues in selecting HCV-infected candidates for anti-viral treatment, Anna S. Lok - Article Reading Aug 21, 2012

Show notes

The recent approval of two protease inhibitors (telaprevir and boceprevir) and the resultant increase in the sustained virological response (SVR) rate when either of these drugs is added to pegylated interferon (PEG-IFN) and ribavirin (RBV) have led to a flurry of patients with hepatitis C virus (HCV) infection seeking treatment.

Treatment options for anti-HCV treatment-experienced patients, Peter Ferenci - Article Reading Aug 21, 2012

Show notes

Treatment failure with pegylated interferon (PEG-IFN)/ribavirin (RBV) dual therapy can be due to either the persistence of hepatitis C virus (HCV) RNA throughout treatment (nonresponse) or the reappearance of the virus after the end of treatment.

HCV infection on-treatment viral kinetics: Do they still have a role? Jordan J. Feld - Article Reading Aug 21, 2012

Show notes

As soon as it was recognized that interferon-based therapy could lead to long-term viral eradication or a sustained virological response (SVR), the search was on for predictors of responses to therapy. With low response rates and the need for prolonged, costly, and difficult therapy, the primary goal was to identify patients who were unlikely to respond to treatment so that fruitless therapy could be avoided.

Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection, Jean-Michel Pawlotsky - Article Reading Aug 21, 2012

Show notes

The recent development of direct-acting antiviral (DAA) molecules that are active on hepatitis C virus (HCV) has raised the concern that resistance may undermine therapy based on DAAs.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected

Our TOPPODCAST Picks

Follow Us

Stay Connected

Clinical Liver Disease

Related Podcasts

1

2

3

4

5

6